Neurotrope Chief Scientific Officer to Present Keynote Address at Sachs Associates’ 1st Annual Neuroscience Biopartnering & Investment Forum

NEWARK, N.J., Feb. 23, 2016 (GLOBE NEWSWIRE) -- Neurotrope, Inc. (NTRP), a clinical-stage company developing a disruptive therapy for the treatment of severe Alzheimer’s disease (AD), today announced that Dr. Daniel Alkon, Neurotrope’s Chief Scientific Officer, is scheduled to present at the Sachs Associates’ 1st Annual Neuroscience Biopartnering & Investment Forum, being held February 23, 2016 at the New York Academy of Sciences in New York City.

Dr. Alkon has been invited to be a keynote speaker at the event, along with executives of Pfizer and Axovant Sciences. His presentation titled “New Directions for the Prevention and Reversal of Neurodegeneration” will take place on Tuesday, February 23, 2016 at 10:45 am EST and lead into the “Advances in Alzheimer’s Disease” Panel.

Dr. Alkon, Neurotrope Chief Scientific Officer and Scientific Director of the Blanchette Rockefeller Neurosciences Institute, commented, “I am honored to present a Keynote address at the 1st Annual Neuroscience Biopartnering & Investment Forum. Alzheimer’s disease is a devastating degeneration of the brain. We now know that AD arises from multiple contributing factors. Effective therapeutics must, therefore, have multiple beneficial effects – so far, not provided by the drugs available today. Neurotrope is clinically testing an AD drug, the PKC epsilon activator, Bryostatin, which has shown the promise of multiple benefits, particularly improvement of synaptic function, stimulation of new synapse formation and repair of damaged synapses. Bryostatin would, thereby, potentially reverse symptoms, restore the lost synaptic wiring of the brain, and relieve debilitating cognitive deficits of the disease. Such reversal, even in patients with severe disease, could offer a paradigm shift in the treatment of AD. The Neuroscience Biopartnering & Investment Forum provides a great opportunity to discuss the exciting advances being made in the science of neurodegenerative diseases, promising treatments under development and Bryostatin's position in the arena."

In addition, Neurotrope Chief Executive Officer Charles S. Ramat together with Dr. Alkon will be presenting at 2:15 pm EST to discuss the Company’s disruptive approach to Alzheimer’s disease treatment, current clinical development plan and upcoming milestones. A live webcast of the presentation will be available online here.

The 1st Annual Neuroscience Biopartnering & Investment Forum will focus on key areas of neurodegenerative diseases and pain management. The forum will draw together an exciting cross-section of early-stage/pre-IPO, late-stage and public companies with leading investors, analysts, money managers and pharmaceutical companies from around the globe. The event offers excellent opportunities to showcase activities and highlight investment and partnership opportunities.

About Neurotrope
Neurotrope BioScience, Inc., a wholly owned subsidiary of Neurotrope, Inc., is at the forefront of biotechnology companies having a focus on developing a novel therapy for the treatment of moderately severe to severe Alzheimer's disease. The scientific basis of our treatment is activation of Protein Kinase C isozymes ε and α by bryostatin, a natural product, which can result in repair of damaged synapses as well as synaptogenesis, reduction of toxic amyloid generation, and enhancement of memory and learning, thus having the potential to improve cognition and behavior in Alzheimer's disease.

Neurotrope is also conducting preclinical studies of bryostatin as a treatment for Fragile X Syndrome and Niemann-Pick Type C disease, two rare genetic diseases for which only symptomatic treatments are currently available. The Food and Drug Administration has granted Orphan Drug Designation to Neurotrope for bryostatin as a treatment for Fragile X Syndrome.

NTRP has exclusively licensed technology from the Blanchette Rockefeller Neurosciences Institute for Alzheimer's disease and Fragile X Syndrome, has a world-wide, exclusive license with the Icahn School of Medicine at Mt. Sinai for Niemann-Pick Type C disease and is partnered with Stanford University to synthesize and find the next generation bryostatin – called bryologs.

Forward-Looking Statements

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. These forward-looking statements include statements regarding the proposed study and timing of initiation, and continued development of use of bryostatin for Alzheimer's disease and other cognitive diseases, and the Company's ability to list its common shares on a major stock exchange. Such forward-looking statements are subject to risks and uncertainties and other influences, many of which the Company has no control over. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Factors that may influence or cause actual results to differ materially from expected or desired results may include, without limitation, the Company's inability to obtain adequate financing, the significant length of time associated with drug development and related insufficient cash flows and resulting illiquidity, the Company's patent portfolio, the Company's inability to expand the Company's business, the Company's inability to meet listing requirements for major stock exchanges, significant government regulation of pharmaceuticals and the healthcare industry, lack of product diversification, availability of the Company's raw materials, existing or increased competition, stock volatility and illiquidity, and the Company's failure to implement the Company's business plans or strategies. These and other factors are identified and described in more detail in the Company's filings with the SEC, including the Company's Quarterly Report on Form 10-Q for the fiscal quarter ended September 30, 2015. The Company does not undertake to update these forward-looking statements.

Please visit for further information.

For additional information, please contact: Neurotrope Bioscience Charles Ramat, Chief Executive Officer 973-242-0005

Source: Neurotrope BioScience